D. Mckearn

Identifying and Overcoming Matrix Effects in Drug Discovery and Development

Yunxia Wang, T. Hall, I. Smukste, 2012 .

Response to docetaxel (D)/carboplatin (C)-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer (HRPC)

P. Kantoff, W. Oh, M. Regan, 2007 .

Response to docetaxel/carboplatin‐based chemotherapy as first‐ and second‐line therapy in patients with metastatic hormone‐refractory prostate cancer

P. Kantoff, W. Oh, M. Regan, 2008, BJU international.